Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides

Authors

Carolina V. Alexander-Savino, Rochester Skin Lymphoma Medical Group, 6800 Pittsford Palmyra Rd, Suite 150, Fairport, NY, 14450, USA.
Catherine G. Chung, Dermatology and Pathology, The Ohio State University, Columbus, OH, 43210, USA.
Elaine S. Gilmore, Rochester Skin Lymphoma Medical Group, 6800 Pittsford Palmyra Rd, Suite 150, Fairport, NY, 14450, USA.
Sean M. Carroll, Rochester Skin Lymphoma Medical Group, 6800 Pittsford Palmyra Rd, Suite 150, Fairport, NY, 14450, USA.
Brian Poligone, Rochester Regional HealthFollow

Department

Research

Document Type

Article

Publication Title

Dermatology and Therapy

Abstract

INTRODUCTION: Treatment of early-stage mycosis fungoides (MF) requires safe, skin-directed therapies. Medication side effects can lead to underutilization of effective therapies. The objective of this study was to assess the use of topical triamcinolone 0.1% ointment as a means of reducing contact dermatitis associated with topical mechlorethamine/chlormethine gel for the treatment of MF. METHODS: This prospective, randomized, open-label study evaluated 28 adults with mycosis fungoides who were eligible for treatment with topical mechlorethamine/chlormethine gel from December 17, 2017 to December 23, 2020. Patients were treated for 4 months with clinical follow-up through 12 months. Patients had half of their lesions also treated with topical triamcinolone 0.1% ointment (while the other half were treated with mechlorethamine/chlormethine alone). The study was self-controlled with separate lesions in the same patient receiving each treatment arm. Treatment arms were determined by the flip of a coin. RESULTS: Twenty-eight patients enrolled (17 men (61%) and 11 women (39%)). Demographics included 25 White, 2 African Americans, and 1 Asian patient. Twenty-five completed the 12-month follow-up. Triamcinolone 0.1% ointment led to increased tolerability of mechlorethamine/chlormethine gel but did not change the efficacy of mechlorethamine/chlormethine. There was a statistically significant 50% decrease in dermatitis (SCORD score) at month 2 in the triamcinolone-treated arm. CONCLUSIONS: Topical triamcinolone ointment is a helpful adjuvant therapy when treating patients with topical mechlorethamine/chlormethine gel. It diminishes inflammation and does not reduce efficacy. The peak incidence of dermatitis in the study occurred in the second and third months. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT03380026.

DOI

10.1007/s13555-022-00681-6

Publication Date

2-5-2022

PubMed ID

35122614

Recommended Citation

Alexander-Savino, C. V., Chung, C. G., Gilmore, E. S., Carroll, S. M., & Poligone, B. (2022). Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides. Dermatology and Therapy https://doi.org/10.1007/s13555-022-00681-6